As of June 10, 2025, N4 Pharma PLC (N4P.L) reports a EV/EBITDA of -2.16.
EV/EBITDA evaluates a company's total value relative to its earnings before interest, taxes, depreciation, and amortization, useful for comparing firms with different capital structures.
Comparing N4 Pharma PLC's EV/EBITDA to Peers
To better understand N4 Pharma PLC's position, it's useful to compare its EV/EBITDA against industry peers. Below are selected comparisons:
| Company | EV/EBITDA |
|---|---|
| N4 Pharma PLC (N4P.L) | -2.16 |
| Photocure ASA (PHO.OL) | 70.04 |
| Friulchem SpA (FCM.MI) | 24.97 |
| Orexo AB (ORX.ST) | 17.57 |
| Pierrel SpA (PRL.MI) | 17.45 |
| Lavipharm SA (LAVI.AT) | 16.31 |
Compared to its competitors, N4 Pharma PLC's EV/EBITDA is about average compared to peers, indicating market valuation in line with industry expectations.